Business, energy, technology, markets and global industry news from Business News Today

Fidelity Management & Research Company

PharmaDeviceNews Fidelity Management & Research Company
Pharma & Biotech

Can Soufflé’s REMEDY platform solve RNA drug delivery challenges beyond the liver?

Soufflé secures $135 million as its FSHD RNA therapy trial recruits patients. Examine the REMEDY platform, Bayer partnership and clinical risks.

Read More
Representative image of RNAi drug discovery research in a biotechnology laboratory. City Therapeutics’ $99.5 million Series B financing puts next-generation RNA interference therapies, including CITY-FXI and CITY-RBP4, in sharper focus as the field expands beyond liver-targeted medicines.
Pharma & Biotech

City Therapeutics raises $99.5m as CITY-FXI and CITY-RBP4 head toward key tests

City Therapeutics has fresh capital, but RNAi’s next test is tissue delivery. See why CITY-FXI and CITY-RBP4 matter now.

Read More